Strain variation and antigenic divergence among Bordetella pertussis circulating strains isolated from patients in Iran

[1]  K. Auranen,et al.  Surveillance of Circulating Bordetella pertussis Strains in Europe during 1998 to 2015 , 2018, Journal of Clinical Microbiology.

[2]  Ross M. Graham,et al.  Bordetella Pertussis virulence factors in the continuing evolution of whooping cough vaccines for improved performance , 2018, Medical Microbiology and Immunology.

[3]  F. Shahcheraghi,et al.  Molecular detection of Bordetella holmesii in two infants with pertussis-like syndrome: the first report from Iran , 2017, Iranian journal of microbiology.

[4]  M. Decker,et al.  Post-licensure safety surveillance study of routine use of tetanus toxoid, reduced diphtheria toxoid and 5-component acellular pertussis vaccine , 2016, Human vaccines & immunotherapeutics.

[5]  V. Sintchenko,et al.  Pertactin negative Bordetella pertussis demonstrates higher fitness under vaccine selection pressure in a mixed infection model. , 2015, Vaccine.

[6]  N. Guiso,et al.  New Data on Vaccine Antigen Deficient Bordetella pertussis Isolates , 2015, Vaccines.

[7]  F. Mooi,et al.  The pertussis problem: classical epidemiology and strain characterization should go hand in hand. , 2015, Jornal de pediatria.

[8]  F. Shahcheraghi,et al.  Virulence Factors Variation Among Bordetella Pertussis Isolates in Iran , 2015, International journal of molecular and cellular medicine.

[9]  F. Shahcheraghi,et al.  Allelic variations between vaccine strains and circulating strains in pxtP of Bordetella pertussis in Iran , 2015 .

[10]  Carol Glaser,et al.  Pertussis Epidemic — California, 2014 , 2014, MMWR. Morbidity and mortality weekly report.

[11]  Daniel R Hogan,et al.  Neonatal cause-of-death estimates for the early and late neonatal periods for 194 countries: 2000–2013 , 2014, Bulletin of the World Health Organization.

[12]  N. Guiso,et al.  Bordetella pertussis and pertactin-deficient clinical isolates: lessons for pertussis vaccines , 2014, Expert review of vaccines.

[13]  P. Bryan,et al.  Safety of pertussis vaccination in pregnant women in UK: observational study , 2014, BMJ : British Medical Journal.

[14]  H. Zeraati,et al.  Genetic Profile Variation in Vaccine Strains and Clinical Isolates of Bordetella pertussis Recovered from Iranian Patients , 2014, Avicenna journal of medical biotechnology.

[15]  V. Sintchenko,et al.  Rapid Increase in Pertactin-deficient Bordetella pertussis Isolates, Australia , 2014, Emerging infectious diseases.

[16]  G. Fedele,et al.  The Virulence Factors of Bordetella pertussis: Talented Modulators of Host Immune Response , 2013, Archivum Immunologiae et Therapiae Experimentalis.

[17]  A. V. D. van der Ark,et al.  Genome-Wide Gene Expression Analysis of Bordetella pertussis Isolates Associated with a Resurgence in Pertussis: Elucidation of Factors Involved in the Increased Fitness of Epidemic Strains , 2013, PloS one.

[18]  J. Zipprich,et al.  California pertussis epidemic, 2010. , 2012, The Journal of pediatrics.

[19]  F. Mooi,et al.  Pulsed-Field Gel Electrophoresis Analysis of Bordetella pertussis Isolates Circulating in Europe from 1998 to 2009 , 2012, Journal of Clinical Microbiology.

[20]  J. Mertsola,et al.  Appearance of Bordetella pertussis Strains Not Expressing the Vaccine Antigen Pertactin in Finland , 2012, Clinical and Vaccine Immunology.

[21]  K. Mills,et al.  Immunity to the respiratory pathogen Bordetella pertussis , 2012, Mucosal Immunology.

[22]  T. Kallonen Evolution of Bordetella pertussis post vaccination , 2011 .

[23]  F. Mooi,et al.  Pertussis: a matter of immune modulation. , 2011, FEMS microbiology reviews.

[24]  F. Mooi,et al.  Studies on Prn Variation in the Mouse Model and Comparison with Epidemiological Data , 2011, PloS one.

[25]  F. Mooi,et al.  Comparative genomics of prevaccination and modern Bordetella pertussis strains , 2010, BMC Genomics.

[26]  A. Abe,et al.  Synergic Effect of Genotype Changes in Pertussis Toxin and Pertactin on Adaptation to an Acellular Pertussis Vaccine in the Murine Intranasal Challenge Model , 2010, Clinical and Vaccine Immunology.

[27]  B. Kříž,et al.  A steady rise in incidence of pertussis since nineties in the Czech Republic. , 2010, Epidemiologie, mikrobiologie, imunologie : casopis Spolecnosti pro epidemiologii a mikrobiologii Ceske lekarske spolecnosti J.E. Purkyne.

[28]  F. Mooi,et al.  An investigation into the cause of the 1983 whooping cough epidemic in the Netherlands. , 2009, Vaccine.

[29]  B. Ewald,et al.  The epidemiology of pertussis in the Australian Capital Territory, 1999 to 2005--epidemics of testing, disease or false positives? , 2007, Communicable diseases intelligence quarterly report.

[30]  F. Mooi,et al.  Bordetella pertussis Strains Circulating in Europe in 1999 to 2004 as Determined by Pulsed-Field Gel Electrophoresis , 2007, Journal of Clinical Microbiology.

[31]  Deborah A. Adams,et al.  Summary of notifiable diseases --- United States, 2005. , 2007, MMWR. Morbidity and mortality weekly report.

[32]  F. Mooi,et al.  Adaptive evolution of the Bordetella autotransporter pertactin , 2006, Journal of evolutionary biology.

[33]  C. Locht,et al.  Temporal analysis of French Bordetella pertussis isolates by comparative whole-genome hybridization. , 2006, Microbes and infection.

[34]  M. Steinbakk,et al.  [Whooping cough--an increasing problem in Norway]. , 2006, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

[35]  O. Bjørnstad,et al.  Evolution and emergence of Bordetella in humans. , 2005, Trends in microbiology.

[36]  F. Mooi,et al.  Analysis of Bordetella pertussis Populations in European Countries with Different Vaccination Policies , 2005, Journal of Clinical Microbiology.

[37]  H. Hallander,et al.  Reference System for Characterization of Bordetella pertussis Pulsed-Field Gel Electrophoresis Profiles , 2004, Journal of Clinical Microbiology.

[38]  R. George,et al.  Genotypic Variation in the Bordetella pertussis Virulence Factors Pertactin and Pertussis Toxin in Historical and Recent Clinical Isolates in the United Kingdom , 2001, Infection and Immunity.

[39]  W. Wattigney,et al.  Molecular epidemiology of Bordetella pertussis by pulsed-field gel electrophoresis profile: Cincinnati, 1989-1996. , 2001, The Journal of infectious diseases.

[40]  T. Popović,et al.  Polymorphism in Bordetella pertussis pertactin and pertussis toxin virulence factors in the United States, 1935-1999. , 2000, The Journal of infectious diseases.

[41]  F. Mooi,et al.  Reemergence of pertussis in the highly vaccinated population of the Netherlands: observations on surveillance data. , 2000, Emerging infectious diseases.

[42]  N. Guiso Bordetella pertussis: why is it still circulating? , 2014, The Journal of infection.

[43]  M. V. Gent,et al.  Molecular studies into the causes of the resurgence of Bordetella pertussis in the face of vaccination , 2013 .

[44]  F. Mooi Bordetella pertussis and vaccination: the persistence of a genetically monomorphic pathogen. , 2010, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[45]  D. Rabczenko,et al.  [Increase in the incidence of pertussis and quality of whole-cell pertussis component of the DTP vaccine produced in Poland. Part I. Potency of DTP vaccine]. , 2004, Przeglad epidemiologiczny.

[46]  F. Mooi,et al.  Adaptation of Bordetella pertussis to vaccination: a cause for its reemergence? , 2001, Emerging infectious diseases.

[47]  E. Hewlett,et al.  Virulence factors of Bordetella pertussis. , 1986, Annual review of microbiology.